About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.48
- USD0.48
- USD0.44
- USD3.32
- 54.40%
- 11M
- 970.00
- 554.81k
- 33M
- 0.24
- -85.50%
Stock News
4 hours ago
Rivian: Near-Term Deliveries Cut Has No Bearing On R2's Future
SeekingAlpha
4 hours ago
Rates Spark: Market Discount Shifts To Un-Discounting Some Recession Risks
SeekingAlpha
5 hours ago
Uber: Accelerates AV Ambitions As Growth Shows Signs Of Stalling
SeekingAlpha
5 hours ago
The Next Frontier In Portfolio Design: Keeping Equities While Adding Gold
SeekingAlpha
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
